Estradiol/etonogestrel intravaginal ring

Drug Profile

Estradiol/etonogestrel intravaginal ring

Alternative Names: ENG-CVR; ENG-E2; ENG/CVR; Etonogestrel containing contraceptive vaginal ring; Etonogestrel/17β-estradiol; Etonogestrel/estradiol intravaginal ring; MK-8342B; SCH 900432

Latest Information Update: 13 Oct 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Class Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Norpregnanes; Progesterone congeners; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Contraception; Dysmenorrhoea

Most Recent Events

  • 28 Sep 2016 Merck Sharp & Dohme terminates phase III trial in Contraception in USA and Puerto Rico (NCT02524288)
  • 26 Sep 2016 Merck terminates phase III trial in Dysmenorrhea in USA (NCT02668822)
  • 16 Sep 2016 Merck terminates phase III trial in Dysmenorrhea in USA, Germany and Finland (NCT02668783; EudraCT2015-004325-14)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top